Treatment Of Patients With Classic Fabry Disease
Provided are methods for the treatment of classic Fabry disease in a patient. Certain methods comprise administering to the patient about 123 mg free base equivalent of migalastat for reducing kidney globotriaosylceramide, stabilizing renal function, reducing left ventricular mass, reducing plasma globotriaosylsphingosine and/or treating gastrointestinal symptoms.
1 - 13 . (canceled)
14 . A method of treating classic Fabry disease in a patient in need thereof, the method comprising administering to the patient an effective amount of migalastat or salt thereof at a frequency of once every other day, wherein the effective amount is about 100 mg to about 150 mg free base equivalent (FBE) and wherein administering the migalastat or salt thereof one or more of:
reduces kidney globotriaosylceramide (GL-3) in the patient;
stabilizes renal function in the patient;
reduces the patient's left ventricular mass (LVM) and/or reduces the patient's left ventricular mass index (LVMi);
reduces plasma globotriaosylsphingosine (lyso-Gb 3 ) in the patient; and/or
treats one or more gastrointestinal symptoms and/or reduces diarrhea symptoms in the patient.
15 . The method of claim 14 , wherein the patient one of more of:
has elevated kidney interstitial capillary GL-3 prior to initiating the administration of the migalastat or salt thereof;
has renal impairment prior to initiating the administration of the migalastat or salt thereof;
has left ventricular hypertrophy (LVH) prior to initiating administration of the migalastat or salt thereof;
has elevated plasma lyso-Gb 3 prior to initiating administration of the migalastat or salt thereof; and/or
has diarrhea prior to initiating administration of the migalastat or salt thereof.
16 . The method of claim 14 , wherein reducing kidney GL-3 comprises reducing GL-3 inclusions per kidney interstitial capillary.
17 . The method of claim 14 , wherein the patient has a mutation in α-Gal A selected from the group consisting of I253T, P259R, G183D, L243F, C174R, D55V/Q57L, G144V, R301Q, G373S, D322E, G325R and Y216C.
18 . The method of claim 14 , wherein the migalastat or salt thereof enhances α-galactosidase A activity.
19 . The method of claim 14 , wherein the effective amount is about 123 mg FBE.
20 . The method of claim 14 , wherein the effective amount is about 123 mg of migalastat free base.
21 . The method of claim 14 , wherein the salt of migalastat is migalastat hydrochloride.
22 . The method of claim 20 , wherein the effective amount is about 150 mg of migalastat hydrochloride.
23 . The method of claim 14 , wherein the migalastat or salt thereof is in an oral dosage form.
24 . The method of claim 23 , wherein the oral dosage form comprises a tablet, a capsule or a solution.
25 . The method of claim 14 , wherein the migalastat or salt thereof is administered for at least 6 months.
26 . The method of claim 14 , wherein administration of the migalastat or salt thereof to a group of classic Fabry patients of provides one or more of:
an average decrease in GL-3 inclusions per kidney interstitial capillary of at least about 0.5 after 6 months of the administration of the migalastat or salt thereof;
a mean annualized rate of change in eGFR CKD-EPI of greater than −1.0 mL/min/1.73 m 2 after 24 months of the administration of the migalastat or salt thereof;
an average decrease in LVMi of at least about 5 g/m 2 after 24 months of the administration of the migalastat or salt thereof;
an average decrease in plasma lyso-Gb 3 of at least about 15 nmol/L after 24 months of the administration of the migalastat or salt thereof and/or
an average decrease in Gastrointestinal Symptoms Rating Scale for Diarrhea (GSRS-D) of at least about 0.5 after 24 months of the administration of the migalastat or salt thereof.
27 - 126 . (canceled)